

Correction

Correction: Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38/p53/p21 and ATM signals

Hongjun Xie^{1,*}, Chong Li^{2,*}, Qiang Dang^{1,*}, Luke S. Chang¹ and Lei Li¹

¹Chawnshang Chang Sex Hormone Research Center, Department of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, China

²CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Science, Beijing 100101, China

*These authors have contributed equally to this work

Published: June 11, 2019

Copyright: Xie et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Due to errors in figure preparation, the image of 22Rv1 displayed in Figure 1B is incorrect. The corrected figure is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2016; 7:1341–1353. <https://doi.org/10.18632/oncotarget.6372>




Figure 1: Prostate cancer recruits more mast cells than normal prostate. B. PCa cells promote mast cell migration. Mast cells (1×10^5) were added in the upper well, we placed non-malignant prostate RWPE-1 cell conditioned medium and PCa C4-2 and CWR22Rv1 (22Rv1) cells conditioned medium to do migration assay. The right panel is the quantitative data for migrated mast cells. Results were presented as the average values and represented as mean \pm SEM. * $p < 0.05$.